{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T08:21:20Z","timestamp":1791015680448,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T00:00:00Z","timestamp":1541376000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00417-018-4168-5","type":"journal-article","created":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T17:32:13Z","timestamp":1541439133000},"page":"49-55","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity"],"prefix":"10.1007","volume":"257","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2315-434X","authenticated-orcid":false,"given":"Emine Alyama\u00e7","family":"Sukgen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf","family":"Ko\u00e7luk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,5]]},"reference":[{"issue":"67","key":"4168_CR1","first-page":"46","volume":"21","author":"C Gilbert","year":"2008","unstructured":"Gilbert C, Muhit M (2008) Twenty years of childhood blindness: what have we learned? Community eye health \/ International Centre for Eye Health 21(67):46\u201347","journal-title":"Community eye health \/ International Centre for Eye Health"},{"key":"4168_CR2","unstructured":"Blencowe H, Lawn JE, Vazquez T, et al. (2010) Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for. PediatrRes 2013;74 Suppl 1:35\u201349"},{"key":"4168_CR3","first-page":"233","volume":"102","author":"WV Good","year":"2004","unstructured":"Good WV, Early Treatment for Retinopathy of Prematurity Cooperative group (2004) Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc 102:233\u2013248","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"4","key":"4168_CR4","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1097\/IAE.0000000000001241","volume":"37","author":"G Zhang","year":"2016","unstructured":"Zhang G, Yang M, Zeng J et al (2016) Shenzhen Screening for Retinopathy of Prematurity Cooperative group. Comparison of intravitreal injection of Ranibizumab versus laser therapy for zone II treatment-requiring retinopathy of prematurity. Retina 37(4):710\u2013717","journal-title":"Retina"},{"key":"4168_CR5","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364:603\u2013615","journal-title":"N Engl J Med"},{"key":"4168_CR6","first-page":"334","volume":"14","author":"H Yetik","year":"2014","unstructured":"Yetik H, Gunay M, Sirop S, Salihoglu Z (2014) Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity - 27-month follow-up results from Turkey. Graefes Arch Clin Exp Ophthalmol 14:334\u2013339","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4168_CR7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1542\/peds.2012-2996","volume":"131","author":"The section on Ophthalmology","year":"2013","unstructured":"The section on Ophthalmology, American Academy of Pediatrics; American Academy of Ophthalmology (2013) American Association for Pediatric Ophthalmology and Strabismus. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 131:189\u2013195","journal-title":"Pediatrics"},{"key":"4168_CR8","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMicm1005605","volume":"364","author":"DF Martin","year":"2011","unstructured":"Martin DF, Maguire MG, Ying GS et al (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897\u20131908","journal-title":"N Engl J Med"},{"key":"4168_CR9","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/archopht.123.7.991","volume":"123","author":"International Committee for the Classification of Retinopathy of prematurity","year":"2005","unstructured":"International Committee for the Classification of Retinopathy of prematurity (2005) The international classification of retinopathy of prematurity revisited. Arch Ophthalmol 123:991\u2013999","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"4168_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000364809","volume":"53","author":"AG Salman","year":"2015","unstructured":"Salman AG, Said AM (2015) Structural, visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethresholdtype 1 retinopathy of prematurity. Ophthalmic Res 53(1):15\u201320. \n                    https:\/\/doi.org\/10.1159\/000364809","journal-title":"Ophthalmic Res"},{"issue":"3","key":"4168_CR11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1159\/000449530","volume":"236","author":"E Alyamac Sukgen","year":"2016","unstructured":"Alyamac Sukgen E, \u00c7\u00f6mez A, Ko\u00e7luk Y, Cevher S (2016) The process of retinal vascularization after anti-VEGF treatment in retinopathy of prematurity:a comparison between Ranibizumab and bevacizumab. Ophthalmologica 236(3):139\u2013147","journal-title":"Ophthalmologica"},{"key":"4168_CR12","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","volume":"98","author":"RL Avery","year":"2014","unstructured":"Avery RL, Castellarin AA, Steinle NC et al (2014) Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol 98:1636\u20131641","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"4168_CR13","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1097\/IAE.0000000000001209","volume":"37","author":"WC Wu","year":"2017","unstructured":"Wu WC, Shih CP, Lien R, Wang NK et al (2017) Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity. Retina 37(4):694\u2013701","journal-title":"Retina"},{"key":"4168_CR14","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","volume":"26","author":"N Ferrara","year":"2006","unstructured":"Ferrara N, Damico L, Shams N et al (2006) Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26:859\u2013870","journal-title":"Retina"},{"key":"4168_CR15","first-page":"340","volume":"78","author":"MK Erol","year":"2015","unstructured":"Erol MK, Coban DT, Sari ES et al (2015) Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity. Arq Bras Oftalmol 78:340\u2013343","journal-title":"Arq Bras Oftalmol"},{"key":"4168_CR16","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1111\/aos.12604","volume":"93","author":"C Zehetner","year":"2015","unstructured":"Zehetner C, Kralinger MT, Modi YS et al (2015) Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomized, prospective trial. Acta Ophthalmol 93:e154\u2013e159","journal-title":"Acta Ophthalmol"},{"key":"4168_CR17","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","volume":"15","author":"N Papadopoulos","year":"2012","unstructured":"Papadopoulos N, Martin J, Ruan Q et al (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab, and bevacizumab. Angiogenesis 15:171\u2013185","journal-title":"Angiogenesis"},{"issue":"8","key":"4168_CR18","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.3109\/02713683.2015.1084643","volume":"41","author":"Z Yi","year":"2016","unstructured":"Yi Z, Su Y, Zhou Y et al (2016) Effects of intravitreal Ranibizumab in the treatment of retinopathy of prematurity in Chinese infants. Curr Eye Res 41(8):1092\u20131097","journal-title":"Curr Eye Res"},{"key":"4168_CR19","first-page":"434","volume":"32","author":"MW Stewart","year":"2012","unstructured":"Stewart MW, Rosenfeld PJ, Penha FM et al (2012) Pharmacokinetic rationale for dosing every2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept(vascular endothelial growth factor trapeze). Retina 32:434\u2013457","journal-title":"Retina"},{"key":"4168_CR20","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.clp.2014.08.011","volume":"41","author":"ME Hartnett","year":"2014","unstructured":"Hartnett ME (2014) Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity. Clin Perinatol 41:925\u2013943","journal-title":"Clin Perinatol"},{"key":"4168_CR21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1080\/08820530701745124","volume":"22","author":"SM Warden","year":"2007","unstructured":"Warden SM, Andreoli CM, Mukai S (2007) The Wnt signaling pathway in familial exudative vitreoretinopathy and Norrie disease. Semin Ophthalmol 22:211\u2013217","journal-title":"Semin Ophthalmol"},{"key":"4168_CR22","doi-asserted-by":"publisher","first-page":"5731","DOI":"10.1523\/JNEUROSCI.19-14-05731.1999","volume":"19","author":"M Sondell","year":"1999","unstructured":"Sondell M, Lundborg G, Kanje M (1999) Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J Neurosci 19:5731\u20135740","journal-title":"J Neurosci"},{"key":"4168_CR23","doi-asserted-by":"publisher","first-page":"10242","DOI":"10.1073\/pnas.97.18.10242","volume":"97","author":"KL Jin","year":"2000","unstructured":"Jin KL, Mao XO, Greenberg DA (2000) Vascular endothelial growth factor: direct neuroprotective effect in vitro ischemia. ProcNatl Acad Sci USA 97:10242\u201310247","journal-title":"ProcNatl Acad Sci USA"},{"issue":"11","key":"4168_CR24","doi-asserted-by":"publisher","first-page":"e3554","DOI":"10.1371\/journal.pone.0003554","volume":"3","author":"M Saint-Geniez","year":"2008","unstructured":"Saint-Geniez M, Maharaj AS, Walshe TE et al (2008) Endogenous VEGF is required for visual function: evidence for a survival role on M\u00fcller cells and photoreceptors. PLoS One 3(11):e3554","journal-title":"PLoS One"},{"key":"4168_CR25","doi-asserted-by":"publisher","unstructured":"Zhou Y, Jiang Y, Bai Y et al (2015) Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab. Graefes Arch Clin Exp Ophthalmol. \n                    https:\/\/doi.org\/10.1007\/S000417-015-2996-0","DOI":"10.1007\/S000417-015-2996-0"},{"key":"4168_CR26","first-page":"1","volume":"17","author":"D Cam","year":"2016","unstructured":"Cam D, Berk AT, Micili SC et al (2016) Histological and Immunohistochemical retinal changes following the intravitreal injection of Aflibercept, bevacizumab, and Ranibizumab in newborn rabbits. Curr Eye Res 17:1\u20138","journal-title":"Curr Eye Res"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-018-4168-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-018-4168-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-018-4168-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T19:17:46Z","timestamp":1572895066000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-018-4168-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,5]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["4168"],"URL":"https:\/\/doi.org\/10.1007\/s00417-018-4168-5","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,5]]},"assertion":[{"value":"16 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethics Committee of the Hospital and complied with the tenets of the Declaration of Helsinki. Informed consent was obtained from the parents of all patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors did not receive any financial support from any public or private sources.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no financial or proprietary interest in any product, method or material described herein.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers\u2019 bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge, or beliefs) in the subject matter or materials discussed in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study. The authors did not receive any financial support from any public or private sources. The authors have no financial or proprietary interest in a product, method, or material described herein.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}